S&P 500   4,133.88 (-0.72%)
DOW   34,075.66 (-0.24%)
QQQ   306.50 (-1.09%)
AAPL   152.96 (-1.09%)
MSFT   270.95 (+1.27%)
META   185.34 (-3.28%)
GOOGL   99.66 (-7.41%)
AMZN   100.30 (-1.77%)
TSLA   199.93 (+1.59%)
NVDA   223.34 (+0.73%)
NIO   10.71 (-1.92%)
BABA   104.66 (-0.80%)
AMD   86.23 (+0.37%)
T   19.15 (-0.52%)
F   13.55 (+0.74%)
MU   61.39 (-1.19%)
CGC   2.80 (-0.71%)
GE   81.68 (-0.52%)
DIS   111.14 (-0.44%)
AMC   5.87 (-5.02%)
PFE   43.80 (+0.48%)
PYPL   81.13 (-2.52%)
NFLX   362.82 (-0.04%)
S&P 500   4,133.88 (-0.72%)
DOW   34,075.66 (-0.24%)
QQQ   306.50 (-1.09%)
AAPL   152.96 (-1.09%)
MSFT   270.95 (+1.27%)
META   185.34 (-3.28%)
GOOGL   99.66 (-7.41%)
AMZN   100.30 (-1.77%)
TSLA   199.93 (+1.59%)
NVDA   223.34 (+0.73%)
NIO   10.71 (-1.92%)
BABA   104.66 (-0.80%)
AMD   86.23 (+0.37%)
T   19.15 (-0.52%)
F   13.55 (+0.74%)
MU   61.39 (-1.19%)
CGC   2.80 (-0.71%)
GE   81.68 (-0.52%)
DIS   111.14 (-0.44%)
AMC   5.87 (-5.02%)
PFE   43.80 (+0.48%)
PYPL   81.13 (-2.52%)
NFLX   362.82 (-0.04%)
S&P 500   4,133.88 (-0.72%)
DOW   34,075.66 (-0.24%)
QQQ   306.50 (-1.09%)
AAPL   152.96 (-1.09%)
MSFT   270.95 (+1.27%)
META   185.34 (-3.28%)
GOOGL   99.66 (-7.41%)
AMZN   100.30 (-1.77%)
TSLA   199.93 (+1.59%)
NVDA   223.34 (+0.73%)
NIO   10.71 (-1.92%)
BABA   104.66 (-0.80%)
AMD   86.23 (+0.37%)
T   19.15 (-0.52%)
F   13.55 (+0.74%)
MU   61.39 (-1.19%)
CGC   2.80 (-0.71%)
GE   81.68 (-0.52%)
DIS   111.14 (-0.44%)
AMC   5.87 (-5.02%)
PFE   43.80 (+0.48%)
PYPL   81.13 (-2.52%)
NFLX   362.82 (-0.04%)
S&P 500   4,133.88 (-0.72%)
DOW   34,075.66 (-0.24%)
QQQ   306.50 (-1.09%)
AAPL   152.96 (-1.09%)
MSFT   270.95 (+1.27%)
META   185.34 (-3.28%)
GOOGL   99.66 (-7.41%)
AMZN   100.30 (-1.77%)
TSLA   199.93 (+1.59%)
NVDA   223.34 (+0.73%)
NIO   10.71 (-1.92%)
BABA   104.66 (-0.80%)
AMD   86.23 (+0.37%)
T   19.15 (-0.52%)
F   13.55 (+0.74%)
MU   61.39 (-1.19%)
CGC   2.80 (-0.71%)
GE   81.68 (-0.52%)
DIS   111.14 (-0.44%)
AMC   5.87 (-5.02%)
PFE   43.80 (+0.48%)
PYPL   81.13 (-2.52%)
NFLX   362.82 (-0.04%)
NASDAQ:AXLA

Axcella Health - AXLA Stock Forecast, Price & News

$0.67
0.00 (-0.47%)
(As of 02/8/2023 10:57 AM ET)
Add
Compare
Today's Range
$0.67
$0.68
50-Day Range
$0.16
$0.92
52-Week Range
$0.16
$2.89
Volume
36,971 shs
Average Volume
1.43 million shs
Market Capitalization
$49.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.25

Axcella Health MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
669.2% Upside
$5.25 Price Target
Short Interest
Healthy
0.67% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.39) to ($0.86) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.96 out of 5 stars

Medical Sector

598th out of 1,029 stocks

Biological Products, Except Diagnostic Industry

95th out of 168 stocks

AXLA stock logo

About Axcella Health (NASDAQ:AXLA) Stock

Axcella Health, Inc. is a biotechnology company. It engages in the research and development of treatment for diseases and improves health using endogenous metabolic modulator, or EMM, and compositions. Its product pipeline includes AXA1665, for the reduction in risk of recurrent overt hepatic encephalopathy, and AXA1125, for non-alcoholic steatohepatitis. The company was founded by Noubar B. Afeyan, Geoffrey von Maltzahn, and David A. Berry on August 27, 2008 and is headquartered in Cambridge, MA.

Receive AXLA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Axcella Health and its competitors with MarketBeat's FREE daily newsletter.

AXLA Stock News Headlines

H.C. Wainwright Reaffirms Their Hold Rating on Axcella Health (AXLA)
The Biggest "Missing Ingredient" in the $7 Trillion EV Market
China has owned the graphite market for decades. But the U.S. just added graphite to a list of super-critical minerals... "essential for America's National Defense." Perfect timing for a "made in America" graphite company looking to mine, manufacture, and recycle graphite for the booming electric car market.
The Biggest "Missing Ingredient" in the $7 Trillion EV Market
China has owned the graphite market for decades. But the U.S. just added graphite to a list of super-critical minerals... "essential for America's National Defense." Perfect timing for a "made in America" graphite company looking to mine, manufacture, and recycle graphite for the booming electric car market.
SVB Securities Keeps Their Buy Rating on Axcella Health (AXLA)
Recap: Axcella Health Q3 Earnings
AXLA Axcella Health Inc.
Axcella Awaits Interim Data From EMMPACT NASH Study
Axcella Health: Q2 Earnings Insights
See More Headlines
Receive AXLA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Axcella Health and its competitors with MarketBeat's FREE daily newsletter.

AXLA Company Calendar

Last Earnings
11/10/2021
Today
2/08/2023
Next Earnings (Estimated)
3/29/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AXLA
Employees
59
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.25
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+681.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$-64,630,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.56 per share

Miscellaneous

Free Float
68,774,000
Market Cap
$49.43 million
Optionable
Not Optionable
Beta
1.58

Key Executives

  • William R. HinshawWilliam R. Hinshaw
    President, Chief Executive Officer & Director
  • Tony Tramontin
    Chief Scientific Officer, Senior VP-R&D
  • Margaret Koziel
    Chief Medical Officer & Senior Vice President
  • Paul Fehlner
    Secretary, Chief Legal Officer & Senior VP
  • Stephen Mitchener
    Chief Business Officer & Senior Vice President













AXLA Stock - Frequently Asked Questions

Should I buy or sell Axcella Health stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Axcella Health in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AXLA shares.
View AXLA analyst ratings
or view top-rated stocks.

What is Axcella Health's stock price forecast for 2023?

4 Wall Street research analysts have issued 1 year price targets for Axcella Health's shares. Their AXLA share price forecasts range from $2.00 to $8.00. On average, they predict the company's share price to reach $5.25 in the next twelve months. This suggests a possible upside of 669.2% from the stock's current price.
View analysts price targets for AXLA
or view top-rated stocks among Wall Street analysts.

How have AXLA shares performed in 2023?

Axcella Health's stock was trading at $0.3275 at the beginning of the year. Since then, AXLA stock has increased by 108.4% and is now trading at $0.6825.
View the best growth stocks for 2023 here
.

Are investors shorting Axcella Health?

Axcella Health saw a decline in short interest in January. As of January 15th, there was short interest totaling 190,000 shares, a decline of 44.2% from the December 31st total of 340,600 shares. Based on an average daily trading volume, of 1,090,000 shares, the short-interest ratio is presently 0.2 days. Currently, 0.7% of the company's stock are sold short.
View Axcella Health's Short Interest
.

When is Axcella Health's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 29th 2023.
View our AXLA earnings forecast
.

How were Axcella Health's earnings last quarter?

Axcella Health Inc. (NASDAQ:AXLA) posted its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.41) EPS for the quarter, beating analysts' consensus estimates of ($0.45) by $0.04.

What is Bill Hinshaw's approval rating as Axcella Health's CEO?

5 employees have rated Axcella Health Chief Executive Officer Bill Hinshaw on Glassdoor.com. Bill Hinshaw has an approval rating of 100% among the company's employees. This puts Bill Hinshaw in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 77.0% of employees surveyed would recommend working at Axcella Health to a friend.

What other stocks do shareholders of Axcella Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Axcella Health investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Evofem Biosciences (EVFM), ADMA Biologics (ADMA), Coty (COTY), Energy Transfer (ET), Myovant Sciences (MYOV), NVIDIA (NVDA), Pfizer (PFE) and Moderna (MRNA).

When did Axcella Health IPO?

(AXLA) raised $76 million in an initial public offering on Thursday, May 9th 2019. The company issued 3,600,000 shares at $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan and SVB Leerink served as the underwriters for the IPO.

What is Axcella Health's stock symbol?

Axcella Health trades on the NASDAQ under the ticker symbol "AXLA."

Who are Axcella Health's major shareholders?

Axcella Health's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David R Epstein, Des Produits Nestle S Societe, Manu Chakravarthy, Margaret Koziel, Paul Fehlner, Robert Crane, Ventures Fund Iv LP Flagship and William Hinshaw.
View institutional ownership trends
.

How do I buy shares of Axcella Health?

Shares of AXLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Axcella Health's stock price today?

One share of AXLA stock can currently be purchased for approximately $0.68.

How much money does Axcella Health make?

Axcella Health (NASDAQ:AXLA) has a market capitalization of $50.20 million. The company earns $-64,630,000.00 in net income (profit) each year or ($1.66) on an earnings per share basis.

How can I contact Axcella Health?

Axcella Health's mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The official website for the company is www.axcellahealth.com. The company can be reached via phone at (857) 320-2200, via email at ir@axcellahealth.com, or via fax at 617-441-6243.

This page (NASDAQ:AXLA) was last updated on 2/8/2023 by MarketBeat.com Staff